Hypothyroidism News and Research

RSS

Hypothyroidism occurs when the thyroid gland does not produce enough thyroid hormone to meet the body’s needs. Without enough thyroid hormone, many of the body’s functions slow down. About 5 percent of the U.S. population has hypothyroidism. Women are much more likely than men to develop hypothyroidism.

Castration-resistant metastatic prostate cancer responds to combination of immune checkpoint inhibitors

Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy have failed, according to early results from a clinical trial led by investigators at The University of Texas MD Anderson Cancer Center presented today at the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.

15 Feb 2019

Vanderbilt study strengthens link between thyroid function and atrial fibrillation

A study by researchers at Vanderbilt University Medical Center has strengthened the link between thyroid function and atrial fibrillation, an irregular heart rhythm that increases the risk of stroke and other heart-related complications.

24 Jan 2019

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism

A new "metal-coordinated" drug-delivery technology potentially could be used to supplement the standard therapy for hypothyroidism, which affects nearly 10 million Americans, and many more patients worldwide, according to results of a study published in the journal Thyroid this month.

15 Oct 2018

Doctor to the stars disciplined over use of controversial menopause therapy

In a conversation with Sarah “Fergie” Ferguson, the Duchess of York, that aired on the Oprah Winfrey Network, Dr. Prudence Hall said age isn't what determines health and vitality.

12 Sep 2018

Standard hypothyroidism treatment inadequate in controlling crucial aspects of the condition

What if the standard treatment for hypothyroidism--insufficient thyroid hormone--is inadequate in controlling some crucial aspects of the condition? That's the provocative question asked, and answered affirmatively with objective data, in a study led by a Rush researcher presented this week in The Journal of Clinical Endocrinology & Metabolism.

22 Aug 2018

Two thyroid medications recalled by FDA

The United States Food and Drug Administration (FDA) have announced the recall of two thyroid medications due to issues with their ingredients.

16 Aug 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications

Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved ZOMACTON for injection in four additional pediatric indications

20 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Online survey shows patient dissatisfaction with hypothyroidism treatments

In the spring of 2017, 12,146 individuals with hypothyroidism responded to an online survey posted on a variety of websites and social media for two months by the Program Committee of the Satellite Symposium on Hypothyroidism, organized by the American Thyroid Association.

8 May 2018

Graphic: Opioid painkiller is top prescription in 11 states

Americans fill about 4.5 billion prescriptions each year, at a cost of more than $323 billion. But what are we actually buying? In 11 states, the top prescriptions are opioid pain pills that are mixtures of acetaminophen and hydrocodone (brand names Vicodin and Norco), according to new data from GoodRx, an online prescription cost service.

22 Mar 2018

Research shows link between chronic fatigue syndrome and lower thyroid hormone levels

New research demonstrates a link between chronic fatigue syndrome (CFS) symptoms and lower thyroid hormone levels. Published in Frontiers in Endocrinology, the study indicates that CFS, a condition with unknown causes, can be explained by lower thyroid hormones -- but may be distinct from thyroidal disease.

20 Mar 2018

Patients on replacement therapy with thyroid hormone may have more comorbidities

People who take replacement thyroid hormone may have more comorbidities and lower quality of life than those who don't take the hormone, a large population-based study from the University of Groningen in the Netherlands reports.

20 Mar 2018

Hypothyroidism News and Research

Further Reading

Castration-resistant metastatic prostate cancer responds to combination of immune checkpoint inhibitors

Vanderbilt study strengthens link between thyroid function and atrial fibrillation

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism

Doctor to the stars disciplined over use of controversial menopause therapy

Standard hypothyroidism treatment inadequate in controlling crucial aspects of the condition

Two thyroid medications recalled by FDA

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Celgene to share new and updated data around novel hematological therapies

Online survey shows patient dissatisfaction with hypothyroidism treatments

Graphic: Opioid painkiller is top prescription in 11 states

Research shows link between chronic fatigue syndrome and lower thyroid hormone levels

Patients on replacement therapy with thyroid hormone may have more comorbidities

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News